Opendata, web and dolomites

transMed SIGNED

Educating the next generation of scientists in translational medicine: Focus on eye diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 transMed project word cloud

Explore the words cloud of the transMed project. It provides you a very rough idea of what is the project "transMed" about.

versa    stage    wealth    groups    joins    students    2bbb    inclusion    integrates    blinding    oculis    evi    broadest    disease    biomedical    transmed    therapies    degree    clinical    hi    educate    retinal    permitting    pamgene    nlo    hctc    drug    establishment    expertise    bedside    secondment    unimore    vitro    academia    ekut    private    hands    commercialisation    course    vivo    obtain    young    toxicological    incu    models    mechanisms    biotech    opportunity    definition    altogether    networking    curriculum    innovative    good    biolog    conferences    bench    collaborations    medicine    gap    degenerations    stages    critical    ongoing    translation    intellectual    successful    property    overview    rds    builds    sppd    vice    public    translational    intersectoral    affairs    untreatable    industry    ulund    manufacturing    biomarkers    data    treatments    rd    basic    pharmacokinetics    respectively    proposes    experiences    regulatory    delays    urgently    sme    competitive    trials    lectures    phd    training    employability    academic   

Project "transMed" data sheet

The following table provides information about the project.

Coordinator
EBERHARD KARLS UNIVERSITAET TUEBINGEN 

Organization address
address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074
website: www.uni-tuebingen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙327˙702 €
 EC max contribution 3˙327˙702 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) coordinator 498˙432.00
2    HASKOLI ISLANDS IS (REYKJAVIK) participant 538˙290.00
3    LUNDS UNIVERSITET SE (LUND) participant 527˙318.00
4    RISE RESEARCH INSTITUTES OF SWEDEN AB SE (BORAS) participant 527˙318.00
5    UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA IT (MODENA) participant 516˙122.00
6    INOCURE SRO CZ (PRAHA) participant 464˙844.00
7    PAMGENE INTERNATIONAL BV NL (DEN HAAG) participant 255˙374.00
8    OCULIS EHF IS (REYKJAVIK) participant 0.00
9    SP PROCESS DEVELOPMENT AB SE (BORAS) participant 0.00
10    2-BBB MEDICINES BV NL (LEIDEN) partner 0.00
11    BIOLOG LIFE SCIENCE INSTITUTE, FORSCHUNGSLABOR UND BIOCHEMICA- VERTRIEB GMBH DE (BREMEN) partner 0.00
12    European Vision Institute EEIG BE (BRUXELLES) partner 0.00
13    HANNOVER CLINICAL TRIAL CENTER GMBH DE (HANNOVER) partner 0.00
14    NLO European Patent and Trademark NL (Amsterdam) partner 0.00

Map

 Project objective

Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed therapies. This is very clearly so in blinding retinal degenerations (RDs), where most are yet untreatable, even with a wealth of basic and pre-clinical research data available. To address this problem, transMed proposes an innovative programme to educate “translational researchers” that focuses on the bench-to-bedside development of treatments for RD.

The transMed consortium joins four academic groups (EKUT, UNIMORE, ULUND, HI) with four non-academic and SME partners (SPPD, INCU, Oculis, PamGene), and five partner organisations (2BBB, BIOLOG, NLO, HCTC, EVI) with intersectoral collaborations already ongoing. Each transMed partner will contribute specific critical expertise to a curriculum covering all major aspects of translational research: From basic research into disease mechanisms and target definition, to drug design and development, in vitro test systems and in vivo disease models, drug delivery systems, biomarkers, good manufacturing practice, toxicological testing and pharmacokinetics, regulatory affairs, intellectual property, all the way to clinical trials and commercialisation.

transMed builds on and integrates three relevant translational projects, which are at the early pre-clinical, late pre-clinical, and early clinical stages, respectively, to provide the project’s Early Stage Researchers with the broadest possible overview. The training is completed by e-lectures, the inclusion of dedicated conferences for young researchers, a secondment and hands-on course programme from industry to academia and vice versa, permitting further insight and networking in the European biotech industry. Altogether, transMed will offer its students the opportunity to obtain a competitive PhD degree in several critical areas of biomedical research, providing for a strong employability in both the private and public sector.

 Deliverables

List of deliverables.
Communication and dissemination I Documents, reports 2020-04-16 14:24:21
Dissemination material Documents, reports 2020-04-16 14:24:16
Project website Websites, patent fillings, videos etc. 2020-04-16 14:24:12

Take a look to the deliverables list in detail:  detailed list of transMed deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Erico Himawan, Per Ekström, Matej Buzgo, Pieter Gaillard, Einar Stefánsson, Valeria Marigo, Thorsteinn Loftsson, François Paquet-Durand
Drug delivery to retinal photoreceptors
published pages: 1637-1643, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.03.004
Drug Discovery Today 24/8 2020-02-04
2019 Arianna Tolone, Soumaya Belhadj, Andreas Rentsch, Frank Schwede, François Paquet-Durand
The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
published pages: 453, ISSN: 2073-4425, DOI: 10.3390/genes10060453
Genes 10/6 2020-02-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSMED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRANSMED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2019)

INNOVATIVE GROUND INTERFACE CONCEPTS FOR STRUCTURE PROTECTION

Read More